MSD provides blockbuster drug free of charge for Evaxion's combination trial

US-based pharmaceutical firm MSD has allowed its drug Keytruda to be used for a phase IIb trial conducted by Evaxion. The Danish biotech company will test its own lead candidate against melanoma in combination with MSD's multi-blockbuster drug.

Photo: MSD / PR

Before the end of the year, Evaxion will begin its phase IIb trial of its lead candidate EVX-01 against metastatic melanoma in a partnership with US-based MSD.

The Danish biotech company reported the news in a press release stating its objective to test its drug in combination with Keytruda, which MSD will provide free of charge for the trial.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs